Physician profile
Daniel J Goodman
NPI 1922075639
$401.82
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2022: $15.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $145.58 | 2019 | |
| Amgen INC. | $47.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.54 | 2019-2022 | |
| Gilead Sciences, INC. | $28.96 | 2019 | |
| Boston Scientific Corporation | $28.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.70 | 2019 | |
| Bardy Diagnostics, INC. | $17.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.